HRS-3802

Phase 1Small molecule

SShandong Suncadia Medicine Co., Ltd.

HRS-3802 is one of 17 small molecule programs targeting Malignant Solid Tumors. It is currently in Phase 1.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Malignant Solid TumorsRecruiting

Malignant Solid TumorsPhase 1

Recruiting

Competition

Competitive Landscape

18 competitors in Malignant Solid Tumors

#DrugCompanyPhaseTrials

Zometa

Pfizer

Phase 3

1 2

Paraplatin

AAvyxa

Phase 2

2 3

Vepesid

AAvyxa

Phase 2

1 4

Platinol

MMcNeil Consumer & Specialty Pharmaceuticals, a Division of McNeil-PPC, Inc.

Phase 2

1 5

SHR-1316

Suzhou Suncadia Biopharmaceuticals Co., Ltd.

Phase 2

1 6

Nab-Sirolimus

MMirati Therapeutics Inc.

Phase 2

1 7

RC148

RRemeGen Co., Ltd.

Phase 2

1 8

JMT103

SShanghai JMT-Bio Inc.

Phase 3

1 9

BP102

Shanghai Hengrui Pharmaceutical Co., Ltd.

Phase 2

1 10

FH-006

JJiangsu HengRui Medicine Co., Ltd.

Phase 2

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q4 2028

Phase 1Recruiting

Malignant Solid Tumors

NCT06770569

Clinical

Trials by Indication[1]

Malignant Solid Tumors1 trial

Safety, Tolerability, and Pharmacokinetics of HRS-3802 Monotherapy in Patients With Malignant Solid Tumors

Recruiting·SShandong Suncadia Medicine Co., Ltd.·Phase 1·NCT06770569·100 enrolled

Sources

References

[1]
ClinicalTrials.gov — 1 trial record for HRS-3802. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — HRS-3802 compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for HRS-3802. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Shandong Suncadia Medicine Co., Ltd. company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 1[1]
Company: SShandong Suncadia Medicine Co., Ltd.

HRS-3802

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q4 2028

Trials by Indication[1]

Malignant Solid Tumors1 trial

References

Drug Info

Quick Facts

Related News